Loading stock data…
ENOV
$23.62+0.18 (+0.77%)
Market ClosedLast close May 1
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Enovis Corporation in the Healthcare sector is trading at $23.62. The stock is currently near its 52-week low of $21.00, remaining 13.1% below its 200-day moving average. Technical signals show neutral RSI of 44 and bearish MACD signal, explaining why ENOV maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$23.62
Potential Upside
5%
Whystock Fair Value$24.80
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$45.00+90.5%
Range$33.00 – $55.00
Fundamentals
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Preventi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.37B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.59
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-55.55%
Volume
Today's trading volume
670,972
Recent News
William Blair Assigns Outperform Rating to Enovis (ENOV)
Enovis Corporation (NYSE:ENOV) is one of the 10 Best Medical Stocks to Buy Under $30. On April 17, William Blair initiated coverage on Enovis Corporation (NYSE:ENOV), giving the stock an Outperform rating. The research firm pointed to valuation opportunities after the stock has dropped over the past two years. William Blair said that Enovis Corporation […]
Enovis (ENOV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Enovis (ENOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omnicell (OMCL) Q1 Earnings and Revenues Surpass Estimates
Omnicell (OMCL) delivered earnings and revenue surprises of +67.94% and +2.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Despite Fast-paced Momentum, Enovis (ENOV) Is Still a Bargain Stock
Enovis (ENOV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Does The Recent Rebound In Enovis (ENOV) Share Price Reflect Its True Worth?
If you are wondering whether Enovis shares are attractively priced today or whether the recent moves represent a value trap, this article breaks down what the current price implies about the company. The stock recently closed at US$26.32, with returns of 7.8% over 7 days and 14.7% over 30 days. Over longer periods, returns include a 17.6% decline over 1 year and deeper falls over 3 and 5 years. Recent attention on Enovis has led investors to focus on how the business is positioned within the...